

## OUR RESOURCES, SKILLS AND CAPABILITIES CONTINUED

## DEVELOPMENT PIPELINE AT 31 JANUARY 2008

| Therapy area               | Compound                          | Mechanism  | Areas under investigation                     | Estimated filing date |         |
|----------------------------|-----------------------------------|--|---|-----------------------|---------|
|                            |                                   |  |   | Europe                | US      |
| <b>PHASE I NCEs</b>        |                                   |  |   |                       |         |
| Cardiovascular             | AZD1175                           | CB1 antagonist   | diabetes/obesity                              |                       |         |
|                            | AZD1305                           | anti-arrhythmic  | arrhythmias                                   |                       |         |
|                            | AZD6370                           | GLK activator  | diabetes                                      |                       |         |
| Gastrointestinal           | AZD2066                           | metabotropic glutamate receptors subtype 5                             | GERD  |                       |         |
|                            | AZD1386                           | vanilloid receptor 1 antagonist  | GERD  |                       |         |
| Neuroscience               | AZD2327                           | enkephalinergic receptor modulator                                     | anxiety and depression                        |                       |         |
|                            | AZD5904                           | inhibitor of myeloperoxidase (MPO)                                     | multiple sclerosis                            |                       |         |
|                            | AZD3241                           | inhibitor of myeloperoxidase (MPO)                                     | Parkinson's disease                           |                       |         |
|                            | AZD0328                           | selective neuronal nicotinic receptor agonist                          | Alzheimer's disease                           |                       |         |
|                            | AZD1940                           | CB receptor agonist  | nociceptive and neuropathic pain              |                       |         |
|                            | AZD2624                           | NK receptor antagonist   | schizophrenia                                 |                       |         |
|                            | AZD1386                           | vanilloid receptor antagonist  | chronic nociceptive pain                      |                       |         |
|                            | AZD2066                           | metabotropic glutamate receptors                                       | chronic nociceptive pain                      |                       |         |
|                            | AZD7325                           | GABA receptor subtype partial agonist                                  | anxiety                                       |                       |         |
|                            | AZD6280                           | GABA receptor subtype partial agonist                                  | anxiety                                       |                       |         |
| Oncology                   | TC-5619 (Targacept)               | neuronal nicotinic receptor agonist                                    | cognitive disorders in schizophrenia          |                       |         |
|                            | AZD1152                           | aurora kinase inhibitor  | solid tumours and haematological malignancies |                       |         |
|                            | AZD4769                           | EGFR tyrosine kinase inhibitor   | solid tumours                                 |                       |         |
|                            | AZD4877                           | cell cycle agent   | solid tumours and haematological malignancies |                       |         |
|                            | AZD8931                           | erbB kinase inhibitor  | solid tumours                                 |                       |         |
|                            | AZD7762                           | CHK1 kinase inhibitor  | solid tumours                                 |                       |         |
|                            | AZD8330 (ARRY-424704)             | MEK inhibitor  | solid tumours                                 |                       |         |
|                            | CAT-8015                          | recombinant immunotoxin  | haematological malignancies                   |                       |         |
| Respiratory & Inflammation | MEDI-538                          | CD19 B cells   | leukaemia/lymphoma                            |                       |         |
|                            | AZD4818                           | CCR1 antagonist  | COPD  |                       |         |
|                            | CAT-354                           | anti-IL-13 antibody  | asthma  |                       |         |
|                            | AZD5904                           | MPO inhibitor  | COPD  |                       |         |
|                            | AZD1744                           | dual CCR3/H1 receptor antagonist                                       | COPD  |                       |         |
|                            | AZD1236                           | matrix metalloproteinase inhibition                                    | COPD  |                       |         |
|                            | AZD9668                           | neutrophil elastase inhibitor  | COPD  |                       |         |
|                            | MEDI-563                          | anti-IL-5R antibody  | asthma  |                       |         |
|                            | MEDI-545                          | anti-IFN $\alpha$ antibody   | SLE, myositis                                 |                       |         |
|                            | Pneumococcal vaccine <sup>1</sup> | pneumococcal vaccine   | streptococcus pneumoniae                      |                       |         |
| Infection                  | AZD3199                           | iLABA  | asthma/COPD                                   |                       |         |
|                            | CAM-3001                          | anti-GM-CSFR antibody  | rheumatoid arthritis                          |                       |         |
|                            | MEDI-534                          | RSV/PIV-3 vaccine  | intranasal immunisation                       |                       |         |
|                            | MEDI-560                          | PIV-3 vaccine  | intranasal immunisation                       |                       |         |
|                            | H5N1                              | H5N1 influenza virus vaccine   | pandemic influenza vaccine                    |                       |         |
|                            | MEDI-564                          | F-protein inhibitor  | RSV treatment                                 |                       |         |
|                            | CMV vaccine                       | CMV vaccine  | cytomegalovirus                               |                       |         |
|                            | MEDI-557                          | YTE – extended half-life RSV MAb                                       | RSV prophylaxis                               |                       |         |
| <b>PHASE II NCEs</b>       |                                   |  |   |                       |         |
| Cardiovascular             | AZD0837                           | thrombin inhibitor   | thrombosis                                    | 2012                  | 2012    |
|                            | AZD4121                           | cholesterol absorption inhibitor                                       | dyslipidaemia                                 |                       |         |
|                            | AZD2207                           | CB1 antagonist   | diabetes/obesity                              |                       |         |
| Gastrointestinal           | AZD3355                           | inhibitor of transient lower oesophageal sphincter relaxations (TLESR) | GERD  | 2011                  | 2011    |
| Neuroscience               | AZD3480                           | neuronal nicotinic receptor agonist                                    | cognitive disorders in schizophrenia          | 2011                  | 2011    |
|                            | AZD3480                           | neuronal nicotinic receptor agonist                                    | Alzheimer's disease                           | 2011                  | 2011    |
|                            | AZD6765                           | NMDA receptor antagonist   | depression                                    |                       |         |
| Oncology                   | Zactima                           | VEGF/EGF TK inhibitor with RET kinase activity                         | medullary thyroid cancer                      | 4Q 2008               | 4Q 2008 |
|                            | AZD6244 (ARRY-142886)             | MEK inhibitor  | solid tumours                                 |                       |         |
|                            | AZD2281                           | PARP inhibitor   | breast cancer                                 |                       |         |
|                            | AZD0530                           | SRC kinase inhibitor   | solid tumours and haematological malignancies |                       |         |
|                            | MEDI-561                          | Hsp 90 inhibitor   | solid tumours                                 |                       | 2010    |
| Respiratory & Inflammation | AZD9056                           | ion channel blocker (P2X7)   | rheumatoid arthritis                          | 2012                  | 2012    |
|                            | AZD1981                           | prostaglandin receptor antagonist                                      | asthma  |                       |         |
|                            | AZD5672                           | chemokine antagonist (CCR5)  | rheumatoid arthritis                          | 2012                  | 2012    |
|                            | MEDI-528                          | anti-IL-9 antibody   | asthma  |                       |         |

## OUR RESOURCES, SKILLS AND CAPABILITIES CONTINUED

| Therapy area                     | Compound                                   | Mechanism  | Areas under investigation                            | Estimated filing date |                       |
|----------------------------------|--|--|--|-----------------------|-----------------------|
|                                  |  |  |  | Europe                | US                    |
| <b>PHASE II NCEs CONTINUED</b>   |  |  |  |                       |                       |
| Infection                        | CytoFab™                                   | anti-TNF-alpha polyclonal antibody                             | severe sepsis  |                       |                       |
|                                  | EBV vaccine <sup>1</sup>                   | Epstein-Barr virus vaccine                                     | post-transplant proliferative disease                |                       |                       |
|                                  | AZD2836                                    | 5a replicon  | hepatitis C  |                       |                       |
|                                  | MEDI-524 (motavizumab)                     | MAB targets F-Protein  | early and late treatment of disease in infants >1 yr |                       |                       |
| <b>PHASE II LINE EXTENSIONS</b>  |  |  |  |                       |                       |
| Gastrointestinal                 | <i>Nexium</i>                              | proton pump inhibitor  | extra-oesophageal reflux disease                     | 2H 2009 <sup>2</sup>  | 2H 2009 <sup>2</sup>  |
| <b>PHASE III NCEs</b>            |  |  |  |                       |                       |
| Cardiovascular                   | AZD6140                                    | ADP receptor antagonist  | arterial thrombosis                                  | 2H 2009               | 2H 2009               |
|                                  | Saxagliptin                                | dipeptidyl peptidase-4 (DPP-4) inhibitor                       | diabetes   | 2H 2009               | 2Q 2008               |
|                                  | Dapagliflozin                              | sodium-glucose cotransporter-2 (SGLT2) inhibitor               | diabetes   | 2010                  | 2010                  |
|                                  | <i>Crestor</i> /ABT-335                    | statin + fibrate fixed combination                             | dyslipidaemia  |                       | 2H 2009               |
| Neuroscience                     | PN400                                      | naproxen + esomeprazole  | signs and symptoms of OA, RA, and AS                 | 1H 2009               | 1H 2009               |
| Oncology                         | <i>Zactima</i>                             | VEGF/EGF TK inhibitor with RET kinase activity                 | NSCLC  | 4Q 2008               | 4Q 2008               |
|                                  | <i>Recentin</i> <sup>3</sup>               | VEGF signalling inhibitor (VEGFR-TKI)                          | NSCLC and CRC  | 2010                  | 2010                  |
|                                  | <i>Recentin</i>                            | VEGF signalling inhibitor (VEGFR-TKI)                          | recurrent glioblastoma                               | 2010                  | 2010                  |
|                                  | ZD4054                                     | endothelin A receptor antagonist                               | hormone-resistant prostate cancer                    | 2011                  | 2011                  |
| Infection                        | Motavizumab (MedImmune)                    | humanised monoclonal antibody                                  | RSV prevention                                       | 1H 2009               | Filed                 |
| <b>PHASE III LINE EXTENSIONS</b> |  |  |  |                       |                       |
| Cardiovascular                   | <i>Atacand</i>                             | angiotensin II antagonist                                      | diabetic retinopathy                                 | 1H 2009               | 1H 2009               |
|                                  | <i>Atacand Plus</i>                        | angiotensin II antagonist/thiazide diuretic                    | 32/12.5 mg, 32/25 mg for hypertension                | 2Q 2008               |                       |
|                                  | <i>Crestor</i>                             | statin   | atherosclerosis                                      | Launched              | Launched              |
|                                  | <i>Crestor</i>                             | statin   | outcomes end stage renal disease                     | 1H 2009               | 1H 2009               |
|                                  | <i>Crestor</i>                             | statin   | outcomes in subjects with elevated CRP <sup>4</sup>  | 2010                  | 2010                  |
|                                  | Saxagliptin/metformin FDC                  | DPP-4 + biguanide FDC  | diabetes   |                       |                       |
|                                  | Dapagliflozin/metformin FDC                | SGLT2 + biguanide FDC  | diabetes   |                       |                       |
| Gastrointestinal                 | <i>Nexium</i>                              | proton pump inhibitor  | peptic ulcer bleeding                                | 2Q 2008               | 2Q 2008               |
|                                  | <i>Nexium</i> sachet formulation           | proton pump inhibitor  | GERD   | Approved <sup>4</sup> | Launched              |
|                                  | <i>Nexium</i> low dose aspirin combination | proton pump inhibitor  | low dose aspirin associated peptic ulcer             |                       | 1H 2009               |
| Neuroscience                     | <i>Seroquel XR</i>                         | D <sub>2</sub> /5HT <sub>2</sub> antagonist                    | schizophrenia  | Approved              | Launched              |
|                                  | <i>Seroquel</i>                            | D <sub>2</sub> /5HT <sub>2</sub> antagonist                    | bipolar maintenance                                  | 2Q 2008               | Filed                 |
|                                  | <i>Seroquel</i>                            | D <sub>2</sub> /5HT <sub>2</sub> antagonist                    | bipolar depression                                   | 1Q 2008               | Launched              |
|                                  | <i>Seroquel XR</i>                         | D <sub>2</sub> /5HT <sub>2</sub> antagonist                    | generalised anxiety disorder                         | 4Q 2008               | 2Q 2008               |
|                                  | <i>Seroquel XR</i>                         | D <sub>2</sub> /5HT <sub>2</sub> antagonist                    | major depressive disorder                            | 3Q 2008               | 1Q 2008               |
|                                  | <i>Seroquel XR</i>                         | D <sub>2</sub> /5HT <sub>2</sub> antagonist                    | bipolar mania  | 1Q 2008               | Filed                 |
|                                  | <i>Seroquel XR</i>                         | D <sub>2</sub> /5HT <sub>2</sub> antagonist                    | bipolar depression                                   | 1Q 2008               | Filed                 |
| Oncology                         | <i>Faslodex</i>                            | oestrogen receptor antagonist                                  | first-line advanced breast cancer                    |                       |                       |
|                                  | <i>Faslodex</i>                            | oestrogen receptor antagonist                                  | adjuvant   |                       |                       |
|                                  | <i>Iressa</i>                              | EGFR-TK inhibitor  | NSCLC  | 2Q 2008               |                       |
| Respiratory & Inflammation       | <i>Symbicort pMDI</i>                      | inhaled steroid/fast-onset, long-acting β <sub>2</sub> agonist | asthma   | Filed <sup>5</sup>    | Launched <sup>6</sup> |
|                                  | <i>Symbicort pMDI</i>                      | inhaled steroid/fast-onset, long-acting β <sub>2</sub> agonist | COPD   | Filed <sup>5</sup>    | 2Q 2008               |
| Infection                        | <i>FluMist</i> (MedImmune)                 | live, attenuated, intranasal influenza virus vaccine           | influenza  | 2Q 2008               | Launched              |

<sup>1</sup> Partnered product.<sup>2</sup> Project Extraesophageal reflux disease (reflux asthma) will be completed but will not result in a regulatory filing.<sup>3</sup> This compound is in Phase II/III development.<sup>4</sup> Approved by EU reference member state, mutual recognition procedure ongoing.<sup>5</sup> To be supplemented in 2008 with data supporting two additional strengths.<sup>6</sup> US approval based on 12 years and above.**Comments**

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

## OUR RESOURCES, SKILLS AND CAPABILITIES CONTINUED

| Therapy area               | Compound                           | Areas under investigation                     |
|----------------------------|------------------------------------|---|
| <b>DISCONTINUED NCEs</b>   |                                    |   |
| Cardiovascular             | AZD2479                            | dyslipidaemia                                 |
|                            | AZD9684                            | thrombosis                                    |
|                            | AGI-1067                           | atherosclerosis                               |
|                            | AZD6610                            | dyslipidaemia                                 |
|                            | AZD1283                            | thrombosis                                    |
|                            | AZD3988                            | diabetes/obesity                              |
| Gastrointestinal           | AZD3118                            | arrhythmias                                   |
|                            | AZD9056                            | inflammatory bowel disease                    |
| Neuroscience               | AZD9272                            | neuropathic pain                              |
|                            | AZD6538                            | neuropathic pain                              |
|                            | AZD3783                            | anxiety and depression                        |
|                            | AZD1080                            | Alzheimer's disease                           |
| Oncology                   | AZD5896                            | solid tumours                                 |
|                            | AZD3646                            | solid tumours and haematological malignancies |
|                            | AZD1689                            | solid tumours                                 |
|                            | MEDI-507 (siplizumab) <sup>1</sup> | PTCL/CTCL                                     |
|                            | MEDI-553 (anti-CD22) <sup>1</sup>  | leukaemia/lymphoma                            |
|                            | MEDI-542 <sup>1</sup>              | solid tumours                                 |
|                            | MEDI-556 <sup>1</sup>              | solid tumours                                 |
|                            | AZD6495                            | range of tumours                              |
|                            | CAT-5001                           | solid tumours                                 |
|                            | AZD5180                            | solid tumours                                 |
|                            | MEDI-552                           | leukaemia/lymphoma                            |
|                            | MEDI-555                           | solid tumours                                 |
|                            | MEDI-562                           | solid tumours                                 |
|                            | CAT-3888                           | hairy cell leukaemia                          |
|                            | AZD9935                            | solid tumours                                 |
|                            | AZD4992                            | breast cancer                                 |
| Respiratory & Inflammation | AZD7928                            | COPD  |
|                            | AZD6703                            | rheumatoid arthritis                          |
|                            | AZD1678                            | asthma  |
|                            | AZD2392                            | asthma  |
|                            | AZD9215                            | asthma  |
|                            | MEDI-552                           | inflammation                                  |
|                            | Anti-IL-6 MAb                      | inflammation                                  |
|                            | anti-chitinase MAb                 | asthma/COPD                                   |
|                            | AZD6357                            | osteoarthritis                                |
| AZD6605                    | osteoarthritis                     |   |
| Infection                  | hMPV MAb                           | respiratory infection                         |

**DISCONTINUED LINE EXTENSIONS**

|                  |  |                    |
|------------------|--|--------------------|
| Cardiovascular   | <i>Crestor</i> outcomes CHF            | CHF                |
|                  | <i>Seloken/Toprol-XL</i>               | HCTZ combination   |
| Gastrointestinal | <i>Nexium</i> NSAID GI US              | ulcer healing      |
|                  | <i>Nexium</i> NSAID GI side effects US | symptom resolution |
| Oncology         | <i>Iressa</i> BC                       | breast cancer      |
| Infection        | <i>Synagis</i> <sup>2</sup>            | RSV                |

<sup>1</sup> Compound entered the pipeline in April 2007, but has since been discontinued.<sup>2</sup> Minor activity ongoing, but will not lead to new indication/formulation.